1 active not recruiting, 1 recruiting. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow 2mg CS0159: new trials by email Literature Review of 2mg CS0159 trials Research Report on 2mg CS0159
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA 2mg CS0159, Placebo - Primary Biliary Cholangitis | Phase 3 | Recruiting | Cascade Pharmaceuticals, Inc | 135 | 2025-12-01 | 2026-11-12 |
| CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis) 2mg CS0159, Placebo - Primary Biliary Cholangitis (PBC) | Phase 2 | Active not recruiting | Cascade Pharmaceuticals, Inc | 75 | 2023-08-07 | 2026-03-13 |
Cascade Pharmaceuticals, Inc (2)
China (2)
Ma Xiong, MD (1) · Rong Deng (1)